A POC Clinical Trial for PTSD with a First-In-Class Vasopressin 1a Receptor Antagonist

Abstract

In this reporting period, year 2 of the project, the major milestones met included obtaining renewal from the responsible local Institutional Review Board (IRB) and the Human Research Protections Office (HRPO) and the DSMB. Patient enrollment began in year 2 with 10 patients currently randomized. In the third year of the project, the major objective will be to continue to recruit and enroll subjects to participate in the clinical study that will test the effect of SRX246, a first-in-class vasopressin 1a receptor antagonist, as a potential new treatment for PTSD.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2017
Accession Number
AD1043345

Entities

People

  • JoAnn Difede
  • Neal G. Simon

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Biomedical Research
  • Clinical Trials
  • Data Analysis
  • Data Management
  • Electronic Mail
  • Health Services
  • Institutional Review Board
  • Medical Personnel
  • Monitoring
  • New York
  • Patent Applications
  • Personnel Management
  • Physicians
  • Pituitary And Hypothalamic Hormones And Analogues
  • Professional Development
  • Quality Of Life
  • Training

Fields of Study

  • Medicine

Readers

  • Clinical Trial Research.